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Objective: To assess the effectiveness of short-wave diathermy (SWD) treatment in the management of
knee osteoarthritis (KOA) and to assess whether the effects are related to the induction of a thermal
effect.
Methods: A systematic literature search was conducted in PubMed, CINAHL, PEDro, EMBASE, SPORTdiscus
and Scholar Google. Included were trials that compared the use of SWD treatment in patients diagnosed
with KOA with a control group (placebo SWD treatment or no intervention) and studies that used high-
frequency electromagnetic energy (i.e., 27.12 MHz) with sufﬁcient information regarding treatment
dosage. Methodological quality of the included studies was assessed in accordance with the PEDro
classiﬁcation scale. A minimum of a 6/10 score was required for inclusion.
Results: Seven studies were included in the ﬁnal analysis. Treatment protocols (dosage, duration, number
of treatments) varied extensively between studies. The meta-analysis of the studies with low mean
power did not favour SWD treatment for pain reduction, while the results of studies employing some
thermal effect were signiﬁcant. No treatment effect on functional performance measures was
determined.
Conclusion: This meta-analysis found small, signiﬁcant effects on pain and muscle performance only
when SWD evoked a local thermal sensation. However, the variability in the treatment protocols makes
it difﬁcult to draw deﬁnitive conclusions about the factors determining the effectiveness of SWD
treatment. More research (using comparable protocols and outcome measurements) is needed to eval-
uate possible long-term effects of thermal SWD treatment and its cost effectiveness in patients with KOA.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Knee osteoarthritis (KOA) is one of the most common forms of
arthritis in the Western world, with a prevalence of 10e15% in
adults over 60 years of age1,2. The primary impairments associated
with KOA include pain, stiffness, joint instability, joint swelling, and
muscle weakness. These impairments result in marked functional
limitations that account for the highest percentage of disability in
walking, stair-climbing, and housekeeping among the non-
institutionalized elderly population, leading to a signiﬁcant
decrease in quality of life3,4.o: Y. Laufer, Department of
th studies, Haifa University,
54.
Laufer), gdar@univ.haifa.ac.il
s Research Society International. PKOA is not a curable disease, and end-stage KOA is frequently
treated by surgical procedures5,6. During the course of the disease,
patients receive a variety of pharmacological and non-
pharmacological treatments aimed at alleviating the signs and
symptoms of the disease and, if possible, slowing its progression7. A
number of medical guidelines have been developed to assist care-
givers in the choice of therapy for the management of KOA, and the
majority of these guidelines include exercise and a variety of
physical therapy modalities6. In fact, 78% of patients with KOA
visiting a medical specialist also see a physical therapist8.
Short-wave diathermy (SWD) is one of the oldest forms of
electrotherapeutic modalities traditionally used by physical thera-
pists to treat symptoms of KOA9e11. SWD typically utilizes elec-
tromagnetic radiation at 27.12 MHz, which is applied in either
a continuous (CSWD) or a pulsed (PSWD) mode, with the latter
delivered in the form of pulse trains9,11. In a survey of 41 Irish
hospital-based physiotherapy departments, CSWD and PSWDwere
speciﬁed as treatments for acute osteoarthritis (OA) by 34.8% andublished by Elsevier Ltd. All rights reserved.
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and 59.4% of the respondents, respectively11. It is generally accepted
that the major physiological effects of CSWD are related to an
induced increase in tissue temperature, which may induce vaso-
dilatation, elevation of pain threshold, reduction in muscle spasm,
acceleration of cellular activity, and increased soft tissue
extensibility11e13.
PSWD is generally used for its athermal effects11e14 which are
probably the result of the ability of cells to absorb energy from
oscillating electrical ﬁelds of deﬁned frequencies and/or ampli-
tudes, thereby provoking or enhancing cellular activity14,15. The
physiological effects attributed to PSWD include increased blood
ﬂow, decreased joint pain and stiffness, reduced inﬂammation,
faster resolution of oedema and accelerated would healing16. The
use of PSWD for arthritic joint treatment has increased dramatically
in the last decade, probably due to the possible link between
increased temperature resulting from CSWD and synovial inﬂam-
matory activity, and between synovial inﬂammatory activity and
worsening of cartilage degeneration in OA13,17. Thus, in a recent
survey in England the availability and use of CSWD has decreased
while the opposite is true for PSWD18.
However, while the introduction of PSWD was driven by it’s
possible athermal effects, studies have demonstrated that PSWD
may also induce an elevation of tissue temperature that is depen-
dent on the total average power delivered19,20. For example,
Bricknell and Watson (1995)21 demonstrated a deﬁnite thermal
sensation, with an average power [standard deviation (SD)] of 10.9
(3.2)W, and Murray and Kitchen (2000)20 determined a ‘possible’
thermal sensation and a ‘deﬁnite’ thermal sensation at a mean (SD)
power of 13.8 (7.1)W and 21.2 (8.3)W, respectively. While a sensa-
tion of warmth at the skin level does not ensure deep tissue
temperature increases, a study with PSWD at an average power of
48 W was shown to increase muscle tissue at 3 cm below the skin
surface by a mean (SD) of 3.78 (1.19)C, which was quite similar to
the increase at skin level19.
In a recent study, Al-Mandeel andWatson (2010)22 examined, in
a well controlled study, the effect of PSWD at a high and low mean
power (24 W and 3 W respectively) and demonstrated signiﬁcant
physiological effects on blood volume and skin temperature
primarily at the high dose treatment. Therefore, the physiological
response to PSWD may also be related to its thermal effects, which
are dose-dependent.
Despite the popularity of this modality, the effectiveness of
CSWD/PSWD for the treatment of KOA has been only sporadically
examined, and many of the earlier studies related to this issue are
characterized by poor experimental design23e26. Several review
papers havebeenpublished to assist the clinician in decisionmaking
regarding the choice of SWD as a treatment modality9,11,13,27. While
these reviews generally recommend the need for additional well-
controlled studies, they do not provide sufﬁcient details to deter-
mine optimal dosage. Furthermore, as these reviews were not
systematic meta-analysis they do not provided sufﬁcient evidence
as to the efﬁcacy of this treatment modality.
One important limitation of these early reviews is that they do
not include randomized controlled studies, conducted more
recently. Furthermore, while two systematic reviews of random-
ized controlled trials have been recently published, these reviews
do not differentiate between studies employing high-frequency
energy (i.e., 27 MHz, frequency) classically referred to as SWD
which can be delivered in a continuous or pulsed form, and those
employing low radio frequency energy (i.e., radio frequency of
1e300 KHz)28,29. These two types of radio frequency energies
involve different technologies and are reported to have different
physiological effects, and therefore should not be combined as
identical (see review by Guo et al., 2011)30.The primary objective of this study was to systematically review
the effectiveness of SWD treatment in themanagement of KOA. The
secondary objective was to assess whether the effects of SWD
treatment are related to the induction of a thermal effect. The
present review was written in accordance with the guidelines
recommended by the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA)31.
Methods
Search strategy
An online search of PubMed (1966 to September 2011), CINAHL
(1982 to September 2011), PEDro (last updated September 5, 2011),
EMBASE (1974 to September 2011), SPORTdiscus (1830 to September
2011), and Scholar Google databases was performed independently
by both authors. The electronic search was completed by a hand
search of bibliographic references of the included studies.
The following medical subject headings by MeSH terms were
used: OA, arthritis, diathermy, short-wave therapy. Keywords were
KOA, knee arthritis, gonarthrosis, short-wave (or shortwave)
diathermy, and short-wave treatment. No publication date or
language was restricted, but the search was restricted to human
studies. The search was initially conducted by the two authors
independently and ﬁnalized by the authors in collaboration. The
last full search was run on September 2011. Duplicated publications
were removed after all databases and reference lists were searched.
The titles and abstracts of all identiﬁed articles were reviewed, with
the full article reviewed whenever deemed necessary to ﬁnalize
a decision about inclusion.
Study selection and eligibility criteria
The authors independently screened all selected citations. The
trials includedwere those that compared the use of SWD treatment
inpatients diagnosedwithKOAwith a control group receivingeither
placebo SWD treatment or no SWD intervention. Trials in which
SWD treatment was supplemented by an additional modality (e.g.,
exercise) were included in the review only when the study also had
a group receiving the additional intervention alone (e.g., exercise).
Only studies that used high-frequency electromagnetic energy (i.e.,
27.12MHz),whetherdelivered ina continuousorpulsedmode,were
selected for the ﬁnal review. In addition, selected studies had to
include sufﬁcient information regarding treatment dosage in order
to determine whether the intervention was thermal or athermal.
Thus, articles that did not provide sufﬁcient information to calculate
meanWatt were included only if the authors speciﬁcally stated that
the treatment was thermal or athermal. While, selection of study
was not limited by study design (other than inclusion of control
group) or outcome measures used, a minimum score of 6/10 on the
PEDro classiﬁcation scale was requited32.
Data extraction
A data extraction sheet was developed by both reviewers, who
then extracted the data independently. Differences between
reviewers in regard to summary of the data were resolved by
consensus. The reviewers contacted one author by e-mail for
information not presented in the published paper33.
Quality assessment
Methodological quality of the included studies was assessed in
accordance with the PEDro classiﬁcation scale32, providing a score
between 0 and 10. The PEDro ratings, which are provided by the
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Global Health, were used whenever available. Studies for which
a PEDro score was not published were scored independently by the
authors, with discrepancies settled by consensus. Studies were
rated between excellent and poor on the basis of the PEDro score, as
follows: 9e10 e excellent; 6e8 e good; 4e5 e fair; <4 e poor.
Data analysis
MetaAnalyst software was used to perform a meta-analysis
where appropriate, that is, when sufﬁciently homogenous data
concerning performance were available. When sufﬁcient data were
not reported to enable calculation of the effect size, the relevant
author was contacted and the necessary datawere requested. Effect
size (Hedges G) was determined conservatively, based on
comparisons of the ﬁnal outcomes of the treatment and control
groups, utilizing standardized scores and continuous random
(DerSimonian-Laird) analysis, while assuming unequal variances.
Results
Study selection
Our literature search from all databases produced 71 studies. Title
and abstracts were viewed to exclude duplicate publications (ﬁve
studies), letters (onepaper), reviewpapers (threepapers), useof radio
frequency other than SWD (18 studies), and pathologies other than
KOA (14 studies). Forty-one studies outof the71were excludedat this
stage, and the remaining 30 were retrieved for full text review.
Nineteen studies were excluded at this stage either because of lack of
appropriate control group or insufﬁcient data concerning treatment
dose. Eleven articles complied with the review selection criteria, of
which twomorewere excluded34,35 since theywere conductedby the
same group. Following consultationwith one of the primary authors
of these studies, only the ﬁnal publication of this series was included
in our analysis36. Two additional studies were excluded at this stage
due to a PEDro score of 4/10. Characteristics of the ﬁnal seven studies
retrieved are summarized in Tables I and II.
Methodological quality
The methodology quality of the included papers according to
the PEDro classiﬁcation scale is presented in Table III. Only one36 of
the studies was scored independently by the authors, while the
remaining scores were provided by the PEDro database. The mean
(SD) PEDro score was 7.28 (1.38), with two studies graded as
excellent (score of 9/10)36,37, and the rest in the good range (score of
6e8/10)33,38e41. One item (blind therapist) was scored positively in
only one study41, and one item (intention to treat) was scored
positively in only two studies36,37. In contrast, three items (baseline
comparable, between-groups comparison, and eligibility criteria)
were scored positively in all included studies. Two of the studies
involved a control group33,38, three a placebo group37,39,40 and two
both a placebo and control groups36,39,41.
Characteristics of included studies
Subjects
The included studies involved 594 patients (527 females), with
274 of them receiving SWD treatment and 320 serving as controls.
The number of subjects per group ranged between 9 and 60, with
a mean of 27 (SDe 12.7). Mean agewas 62.5 years (SD e 5.07). KOA
was conﬁrmed in all subjects on the basis of radiological changes,
with the exception of one study37 in which eligibility was based on
the diagnostic criteria of the American College of Rheumatology.Intervention
Treatment dosage: Information regarding treatment dosage
varied between studies. One study did not specify whether they
used a continuous or pulsed mode nor were any other dosage
parameters identiﬁed that could help us determine mean power or
energy38. However, this study indicated speciﬁcally that intensity
was set based on each individual’s sensation of warmth determined
as “a mild but pleasant sensation of heat.” Of the remaining studies,
only one used a continuous mode, with a relatively high mean
power in the range of 120e132Wand a total energy of 108e118 KJ,
inducing a strong thermal effect33 (as determined through personal
communication with the author).
Duration and number of treatments: The shortest treatment
duration was 15 min33,41, and the longest duration was 38 min36,
with 20 min being the most common treatment duration36e40. The
total number of treatments varied from six treatments delivered
over a period of 2 weeks39 to a total of 24 delivered over a period of
8 weeks33. The mean (SD) number of treatments was 11.14 (5.92),
carried out over a mean (SD) period of 3.71 (1.97) weeks.
Treatment groups and additional intervention
The number of treatment groups varied between two and ﬁve.
The control groups received either placebo SWD or no SWD
treatment. While the majority of the studies included only one
group receiving SWD treatment, three studies involved two SWD
treatment groups differing in dosage36,39,40.
In three of the studies, the patients receiving SWD treatment
were not offered any additional intervention during the treatment
period36,39,40. Additional interventions in the remaining studies
included exercise and hot packs.
Treatment effects
A summary of treatment effects reported in the various studies
is presented in Table I (last column). Effect sizes and 95% conﬁdence
interval (CI) of the primary outcome measures, as well as the
pooled effects computed when data were available for more than
one study, are presented in Table IV. The P-values reported in the
original studies are included in this table whenever insufﬁcient
data were available to calculate the effect size.
Body structure and function domain
All of the included studies assessed pain either using a visual
analogue scale (VAS) or a Numeric Pain Rating Scale (NPRS). In two of
these studies, pain was determined by the mean response to ﬁve
questions, as rated on a VAS, which comprised the pain subscale in
the Western Ontario and McMaster Universities osteoarthritis
(WOMAC) questionnaire38,40. Results from all but one study37 were
pooled for the meta-analysis. However, since three studies involved
two treatment groupsdiffering in SWDdosage, the results of only one
treatment group per study was included in the overall pooled anal-
ysis so as to account for possiblewithin-study bias. The group chosen
was the one that demonstrated the strongest positive effect36,39,40.
Overall analysis did not quite reach signiﬁcance in terms of pain
reduction [Effect size (CI) 0.414 (0.857, 0.030)] (Table IV, Fig. 1).
The study that could not be pooled in themeta-analysis, reported no
such effect37. In an attempt to identify whether treatment dose
explained the inconsistency between groups, separate analyseswere
conducted for the studieswithmeanpower10W39,40 and for those
with mean power greater than 10 W. The effect estimates of the
studies with low mean power did not favour SWD treatment, while
the pooled results of studies employing some thermal effect were
statistically signiﬁcant [Effect size (CI) 0.334 (0.643, 0.026)].
The results of two out of the three studies that examinedmuscle
strength with a focus on isokinetic knee motion could be pooled for
Table I
Study characteristics
Study Age
Mean (SD)
BMI
Mean (SD)
Gender M/F Groups No. per Group Test time Outcome measures Results
Akyol, 201038 57.8 (10.7)
56.6 (8.1)
31.1 (5.2)
30.8 (3.6)
Females only Gr1: SWD þex’
Gr 2: Control
(ex’ only)
20
20
Pre; Postz; &
3 mo. FU
Body structure & function
Pain VAS; isokinetic torque of knee ﬂexors &
extensors; Beck depression inventory
Activity
6 min walk test; WOMAC; SF-36
Signiﬁcant time effect on
all measures; no group effect
Callaghan, 200539 59.5 (6.7)
58.3 (7.3)
63.5 (7.9)
29.9 (4.3)
26.8 (3.9)
27.2 (4.5)
14/13 Gr 1: Low SWD
Gr 2: High SWD
Gr 3: Placebo
9
9
9
Pre & Postz Body structure & function
ROM; pain VAS; peak concentric torque of knee
extensors; joint inﬂammation measured with
radio-leucoscintigraphy
Activities
13 m gait velocity
No time effect;
No group effect except for
ROM which improved
signiﬁcantly more in the
placebo group
Cetin, 200833 59.8 (11.6)
61.9 (8.6)
57.6 (7.3)
61.1 (8.3)
58.9 (9.1)
27.9 (4.2)
29.5 (4.6)
29.8 (5.7)
27.7 (4.2)
27.4 (4.2)
Females only Gr 1: SWD þ HP þ ex’
Gr 2: TENS þ HP þ ex’
Gr 3: US þ HP þ ex’
Gr 4: Control
(HP þ ex’)y
Gr 5: Control (ex’)
20
20
20
20
20
Pre; Postz Body structure & function
Pain VAS; isokinetic strength knee extension
Lequesne Index of knee
Activity
50 m walk velocity
Greater signiﬁcant decreases
in pain, muscle strength in
SWD Gr. vs control Gr;
signiﬁcant time effect on
walking velocity with no
group effect
Fukuda, 201136 62.0 (8.0)
63.0 (9.0)
57.0 (9.0)
61.0 (10.0)
29.4 (4.5)
27.1 (4.2)
27.6 (3.7)
26.7 (3.0)
Females only Gr 1: Low SWD
Gr 2: High SWD
Gr 3: Placebo
Gr 4: Control*
32
31
23
35
Pre; Postz; &
12 mo. FU
Body structure & function
Pain VAS
Activities
KOOS questionnaire
Signiﬁcant reduction in
pain and improvement in
function of both low and high
SWD vs control or placebo
groups. No differences between
treatment groups
Klaber Moffett, 199641 62.7 (8.7)
63.5 (10.5)
64.4 (10.3)
e 34/58 Gr 1: SWD
Gr 2: Placebo
Gr 3: Control *
30
30
30
46 knee, 46 hip
Pre; postz; 4 &
12-week FU
Body structure & function
Daily pain diary (0-100 scale); General Health
questionnaire; (ADL & ROM assessed
but no reported)
Signiﬁcant time effect; no
group effect for any
of the measures
Laufer, 200540 72.7 (6.4)
74.8 (6.6)
73.3 (6.9)
e 21/82 Gr 1: Low SWD
Gr 2: High SWD
Gr 3: Placebo
32
38
33
Pre; postz;
12-week FU
Activities
Timed Get-Up & Go Test; stair negotiation;
3-min walk; WOMAC
Signiﬁcant time effect for pain
and stiffness, with no group effect
Rattanachaiyanont, 200837 63.3 (7.6)
62.5 (8.5)
25.6 (4.0)
26.2 (4.2)
Females only Gr1: SWD þ ex
Gr 2: Placebo þ ex
53
60
Pre; Postz; &
3-week FU
Activity
100 m walking velocity; stair negotiation time;
Modiﬁed WOMAC; global assessment;
patient satisfaction
Signiﬁcant time effect; no
group effect
M/F e male/female; ex’ e exercises; FU e follow up; ADL e activities of daily living; WOMAC eWestern Ontario MacMaster Questionnaire; SF-36 e short form (36) health survey.
* Control ¼ no intervention.
y The control group used for meta-analysis.
z Post e following the completion of last treatment.
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Table II
Treatment characteristics
Study Unit/company Energy transfer
method
Electrode/
applicator
Continuous/
pulsed
Thermal/
athermal
Peak
(W)
Pulse duration
(msec)
Freq.
(Hz)
Mean
Watt
Rx duration
(min)
Energy
(KJ)
No.
of Rxs
Other interventions
Akyol, 201038 Curapuls 419/
Enraf-Nonius
Inductive Coil e Mild thermal e e e e 20 e 4 wks;
total: 12
Both groups:
isokinetic exercise
Callaghan, 200539 Megapulse/EMS Inductive Drumy Gr. 1: Pulsed
Gr. 2: Pulsed
Athermal
Possible thermal
200
400
400
400
10
20
20
20
12*
24*
2 wks;
total: 6
None
Cetin, 200833 Curapuls
419/Enraf-Nonius
Capacitive e Continuousy Thermaly e e e 120e132y 15 108e118*,y 8 wks;
total 24
Groups 1e4:
HP & exercise
Group 5: exercise
Fukuda, 201136 Diatermed II/Carci Capacitive Soft electrodes Gr. 1: Pulsed
Gr. 2: Pulsed
Possible thermal
Possible thermal
250
250
400
400
145
145
14.5
14.5
19
38
17
33
3 wks;
total: 9
None
Klaber Moffett, 199641 Ultramed/Bosch Inductive Drum (circuplode) Pulsed Possible thermal e e 82 23 15 20* 3 wks;
total: 9
Exercise & diet
instructions to
all groups
Laufer, 200540 Curapuls 670/Enraf-Nonius Inductive Drum (circuplode) Gr. 1: Pulsed
Gr. 2: Pulsed
Athermal
Mild thermal
200
200
82
300
110
300
1.8
18
20
20
2.1*
21*
3 wks;
total: 9
None
Rattanachaiyanont, 200837 Ultramed/Bosch Capacitive Condenser plate Pulsed Athermal 300 e e 3.2 20 3.8* 3 wks;
total: 9
Both groups:
exercise, NSAID
as needed
* Calculated by the authors using the following formula: total energy (J) ¼ mean power (W)  application time (s).
y Personal communication.
Table III
Summary of methodological quality based on the PEDro classiﬁcation scale
Study Overall Eligibility
criteriay
Random
allocation
Concealed
allocation
Baseline
comparable
Blind
subject
Blind
therapist
Blind
assessor
Adequate
follow-up
Intention
to-treat
Between-group
comparison
Point estimates
& variability
Akyol, 201038 7 Yes Yes Yes Yes No No Yes Yes No Yes Yes
Callaghan, 200539 6 Yes Yes Yes Yes No No Yes No No Yes Yes
Cetin, 200833 6 Yes Yes No Yes No No Yes Yes No Yes Yes
Fukuda, 2011* 36 9 Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Klaber Moffett, 199641 8 Yes Yes No Yes Yes Yes Yes Yes No Yes Yes
Laufer, 200540 6 Yes No No Yes Yes No Yes Yes No Yes Yes
Rattanachaiyanont, 200837 9 Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Summary (Yes/no) 7/7 6/7 4/7 7/7 4/7 1/7 7/7 6/7 2/7 7/7 7/7
* Rated by authors.
y Eligibility criteria item does not contribute to total score.
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Table IV
Summary of treatment effects (reported P value, effect size and 95% CI)
Study name Measure Reported P value* Effect size 95% CI (lower & upper)
Body structure and function domain
Pain
aAkyol, 201038 VAS 0.493 1.123 0.137
bAkyol, 201038 WOMAC (pain) 0.113 0.734 0.507
cCallaghan, 200539 (LD) VAS 0.473 1.365 0.419
dCallaghan, 200539 (HD) VAS 0.328 1.212 0.556
eCetin, 200833 VAS 0.098 0.718 0.523
fFukuda, 201136 (LD) NPRS 1.439 2.068 0.810
gFukuda, 201136 (HD) NPRS 0.982 1.579 0.386
hKlaber-Moffett, 199641 NPRS 0.026 0.594 0.542
iLaufer, 200540 (LD) WOMAC (pain) 0.082 0.384 0.549
jLaufer, 200540 (HD) WOMAC (pain) 0.119 0.606 0.368
kRattanachaiyano, 200837 WOMAC (pain) NS e e e
Pooled effect: Overall: a, d, e, f, h & j L0.408 L0.837 0.022
Pooled effect Thermal: a, d, e, g, h, & j L0.327 L0.627 L0.028
Pooled effect Athermal: c & i L0.060 L0.535 0.415
Muscle strength
aAkyol, 201038 Isokinetic left knee extension at 60/s 0.404 0.223 1.030
bCetin, 200833 Isokinetic left knee extension at 60/s 0.528 0.104 1.159
cCallaghan, 200539 (LD) Concentric knee extension 90/s 0.348 0.277 0.973
dCallaghan, 200539 (HD) Concentric knee extension 90/s 0.492 0.138 1.122
Pooled effect: a & b 0.465 0.020 0.910
Joint inﬂammation
Callaghan, 200539 (LD) Radio-leucoscintigraphy 0.289 0.912 0.334
Callaghan, 200539 (HD) Radio-leucoscintigraphy 0.218 0.404 0.840
ROM
Callaghan, 200539 (LD) Knee joint 0.398 1.025 0.228
Callaghan, 200539 (HD) Knee joint 0.376 0.250 1.002
Activity domain
Activity questionnaires
aAkyol, 201038 WOMAC (function) 0.247 0.869 0.376
bCetin, 200833 Lequesne Index 0.022 0.642 0.598
cFukuda, 201136 (LD) KOOS 1.141 0.562 1.721
dFukuda, 201136 (HD) KOOS 0.999 0.425 1.572
eLaufer, 200540 (LD) WOMAC (function) 0.048 0.418 0.515
fLaufer, 200540 (HD) WOMAC (function) 0.081 0.567 0.406
gRattanachaiyano, 200837 WOMAC (total) NS
Pooled effect of a & f 0.144 0.527 0.240
Gait performance
Akyol, 201038 6 MWT (m) 0.088 0.532 0.708
Callaghan, 200539 (LD) 13 m walk (s) 0.140 0.785 1.065
Callaghan, 200539 (HD) 13 m walk (s) 0.177 1.103 0.749
Cetin, 200833 50 m walk (time) 0.110 0.730 0.511
Laufer, 200540 (LD) Timed Up and Go (s) 0.001 0.465 0.468
Laufer, 200540 (HD) Timed Up and Go (s) 0.216 0.703 0.272
Laufer, 200540 (LD) Stair climbing (s) 0.035 0.501 0.432
Laufer, 200540 (HD) Stair climbing (s) 0.144 0.631 0.343
Laufer, 200540 (LD) Stair descending (s) 0.002 0.464 0.468
Laufer, 200540 (HD) Stair descending (s) 0.153 0.640 0.334
Laufer, 200540 (LD) 3 min walk (m) 0.021 0.445 0.488
Laufer, 200540 (HD) 3 min walk (m) 0.227 0.261 0.715
Rattanachaiyano, 200837 100 m walk (m/min) NS e e e
Rattanachaiyano, 200837 Stair negotiation (s) NS e e e
Quality of life
Klaber-Moffett, 199641 General Health questionnaire-30 0.293 0.157 0.992
WOMAC eWestern Ontario and McMaster Universities Osteoarthritis questionnaire; LD elow dose; HD e high dose; 6 MWT e 6 min walk test.
* P values reported when effect size could not be calculated.
Y. Laufer, G. Dar / Osteoarthritis and Cartilage 20 (2012) 957e966962meta-analysis33,38,39. Both studies33,38 examined strength at the
same three speeds (60, 120 and 180/s), and similar positive results
were obtained for all speeds. However, the analysis was conducted
only for the 60/s measure, which requires the greatest exertion.
Overall analysis indicates a signiﬁcant effect of SWD treatment on
muscle strength [Effect size (CI) 0.465 (0.020, 0.910)] (Fig. 2).
One study39 examined the effect of SWD treatment on joint inﬂam-
mation following six treatments with either athermal SWD dosage
(10 W) or mild thermal dosage (20 W), using radio-leucoscintigraphy.
Their results showed no treatment effect on joint inﬂammation.Range of motion (ROM)39 was assessed by only one study
employing mild thermal treatment, indicating no beneﬁcial effect
of SWD treatment on ROM.
Activity domain
Activity questionnaires. Six studies provided the results of self-report
physical function questionnaires. Three studies using the WOMAC
questionnaire37,38,40, two of which were pooled38,40, indicated no
beneﬁcial effects [Effect size 0.144, CI (0.527, 0.240)] (Fig. 2). Rat-
tanachaiyanont (2008)37 did not supplyenoughdata to be included in
Fig. 1. Meta-analysis for pain reduction following SWD treatment.
Y. Laufer, G. Dar / Osteoarthritis and Cartilage 20 (2012) 957e966 963the pooled analysis, but no signiﬁcant differences were reported
between the groups following treatment. One study33 used the
Lequesne Index to assess activity level, reporting greater improve-
ment in the treated groups in comparisonwith the control group. One
study34 used the Knee Injury and OAOutcome Score (KOOS) to assess
patient activity and found signiﬁcant differences in the groups that
received SWD treatment (low and high dose), as compared to the
control or placebo groups (range ¼ P < 0.05  P < 0.001).
Gait performance. Five of the studies utilized gait performance tests
to assess treatment effect. No pooled effects could be calculated dueto differences in performance measures. No signiﬁcant effects on
walking capabilities were determined in these studies.
Quality of life. One study included self-report questionnaires in
regard to quality of life41 reporting no signiﬁcant positive effect of
SWD on quality of life compared with control groups.
Adverse events
One study described a few side effects that included mild pain,
swelling and feeling of vasodilatation, these events were similar in
Fig. 2. Meta-analysis for muscle strength and WOMAC questionnaire following SWD treatment.
Y. Laufer, G. Dar / Osteoarthritis and Cartilage 20 (2012) 957e966964both the group receiving SWD treatment and the group receiving
placebo SWD37. Therefore, they cannot be directly related to the
SWD treatment. None of the remaining studies reported on
whether or not there were any adverse events following treatment.
Discussion
A total of seven studies examining the effects of SWD treatment
on the management of KOA were identiﬁed in this review. Due to
the high variability in the outcome measures used in these studies,
a meta-analysis was carried out only for pain, muscle strength, and
functional abilities, as reported in the WOMAC questionnaire. This
meta-analysis pointed to the strong possibility of an overallimmediate effect following the completion of the last treatment
session on pain (Table IV, Fig. 1). An additional separate analysis by
thermal dose showed that the positive effect on pain perception is
achieved only when the treatment involves at least some degree of
thermal sensation. However, the analysis yielded no short-term
follow-up effect38,40,41, indicating that whatever beneﬁt may be
gained immediately post-treatment in terms of pain management
is lost within a 9e12-week period.
The meta-analysis also demonstrated an immediate positive
effect on muscle strength when SWD treatment was combined
with an exercise program, in contrast to exercise alone (Table IV,
Fig. 2). Knee pain associated with joint movement and muscle
contraction may inhibit full muscle activation through central
Y. Laufer, G. Dar / Osteoarthritis and Cartilage 20 (2012) 957e966 965mechanisms42, which in turn may lead to weakness and disuse
atrophy. Thus, pain in patients with KOA has been shown to
correlate with quadriceps muscle weakness43. It is possible that the
effects of the SWD treatment on knee pain may have contributed to
the observed improvement in strength. However, these changes in
pain and muscle strength did not carry over to the subjects’ activity
level, as assessed either by the WOMAC questionnaire or by the
various gait performance measures (Table IV, Fig. 2).
In terms of self-reported functional ability, one study reported
positive results using the KOOS questionnaire36, while a second
study using the Lequesne Index reported no effect on functional
ability33. The remaining three studies37,38,40 examining the effect
on functional ability used the WOMAC questionnaire. However,
only the two of them that could be pooled indicated no signiﬁcant
effect38,40.
The variability in the treatment protocols makes it impossible to
draw deﬁnitive conclusions about the factors determining the
effectiveness of SWD treatment. To illustrate this point, we can
consider the two studies which received the highest PEDro score
(9/10)36,37. Whereas the study by Fukuda et al. (2011)36, demon-
strated signiﬁcant improvements in both pain intensity and func-
tional ability, no such effects were demonstrated by
Rattanachaiyanont et al. (2008)37. Although several treatment
parameters, such as mode of energy delivery and number of
treatment sessions, were the same in both studies, there were at
least two important factors which could have contributed to the
conﬂicting results. First, treatment dose was almost four times
higher in the study with the positive results (14.5 W vs 3.2 W).
Second, while no other intervention was combined with the high-
dose SWD treatment36, in the second study, an exercise program
was delivered to both the SWD and the control groups. Since
research has repeatedly demonstrated the beneﬁts of an exercise
program in this population44, one possible explanation for the
differing results may be that the contribution of the SWD treatment
was over-ridden by the effects of the exercise intervention. Yet, two
other studies in our review also included an exercise intervention,
with one demonstrating no beneﬁt from adding SWD treatment to
an exercise program38, while the other demonstrated that the
group receiving SWD treatment, hot packs and exercise had more
improvement in pain level and muscle strength than the group
receiving hot packs and exercise alone33. Thus, further research is
necessary to determine what aspects of the treatment are crucial
for its success.
One of our goals in this study was to examine whether inducing
a thermal effect has a signiﬁcant impact on the effectiveness of
SWD treatment. However, deciding whether a thermal effect was
induced in the reviewed articles turned out to be more complicated
than expected. Only some of the studies reported whether or not
a thermal sensation was induced33,38,40, and others used different
deﬁnitions. For example, Klaber Moffett et al. (1996)41 employed
a dose of 23 W and considered it sub-thermal, whereas Laufer et al.
(2005)40 reported that at 18 W, patients experienced a mild
sensation of warmth. Therefore, in our sub-analysis, which
attempted to differentiate studies by the degree of thermal sensa-
tion, we included in the athermal group only two studies with such
a low dosage that a thermal effect could be deﬁnitely ruled out37,40.
This separate analysis indicated the importance of at least some
thermal effect for SWD treatment to be beneﬁcial. Furthermore, it
should be noted that no adverse effects were reported in any of the
studies, indicating the safety of using SWD at a level inducing
a mild thermal sensation in patients with KOA.
As stated above, a primary limitation of this review is that the
meta-analysis for most outcome categories included only some of
the studies, due to the high variability in the outcome measures
used and to the lack of sufﬁcient information necessary to conducta meta-analysis. Future ability to conduct a more comprehensive
meta-analysis would be enhanced by better standardization of the
outcome measures used for the evaluation of patients with KOA at
all levels of the International Classiﬁcation of Functioning,
Disability and Health (ICF), as well as provision of all the data
necessary to conduct a meta-analysis (group means and SDs pre-
and post-treatment). Inconsistencies in the reporting of the treat-
ment dosage, high variability in the treatment protocols, and lack of
long-term follow-up studies further limited our ability to reach
more deﬁnitive conclusions. Furthermore, our review focused
primarily on the effects of SWD treatment and did not attempt to
examine its value or its cost effectiveness in comparisonwith other
treatment modalities.
Practical and research implications
In conclusion, SWD treatment appears to be effective for
decreasing pain and increasing muscle strength in patients with
KOA. However, this effect is noticed primarily immediately post-
treatment and is lost by 12 weeks following treatment. No deﬁni-
tive answers can be provided regarding the effects of SWD treat-
ment on other impairments (e.g., joint inﬂammation) or on
functional ability. The results indicate that athermal treatment is
probably not beneﬁcial. Since the more modern SWD equipment is
menu driven, clinicians are encouraged to determine that the dose
provided by the menu is sufﬁcient to induce at least some thermal
sensation.
More research, especially research using comparable samples,
protocols and outcome measurements, is needed to evaluate the
long-term effects of treatment and its cost effectiveness in patients
with OA of the knee as well as OA of other joints.
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